Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

In a report released today, from Jefferies maintained a Buy rating on Bristol-Myers Squibb, with a price target of $68.00. In addition to Jefferies...

Jefferies Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD – Research Report), Bristol-Myers...

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Bristol-Myers Squibb (BMY) and PACS Group Inc (PACS)

Jefferies analyst maintained a Buy rating on Bristol-Myers Squibb today and set a price target of $68.00. In addition to Jefferies, Bristol-Myers S...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acrivon Therapeutics, Inc. (ACRV – Research Report...

Analysts Conflicted on These Healthcare Names: Acrivon Therapeutics, Inc. (ACRV) and Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb ( ($BMY) ) has shared an update. On November 10, 2025, BMS Ireland Capital Funding, a subsidiary of Bristol-Myers Squibb, comp...

Bristol-Myers Squibb Completes €5 Billion Note Offering

With the S&P 500 ($SPX) up 22.8% over the past six months and the Nasdaq ($NDX) surging an even stronger 36.0%, there’s no denying that equities ar...

How MRK, ABBV, and BMY Could Rescue Investor Portfolios in a Downturn

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $47.00. The company’s shares op...

Bristol-Myers Squibb (BMY) Receives a Hold from BMO Capital

Bristol-Myers Squibb ( ($BMY) ) has shared an announcement. On November 3, 2025, Bristol-Myers Squibb announced the commencement of cash tender off...

Bristol-Myers Squibb Launches $7 Billion Tender Offer

In a report released today, Carter Gould from Cantor Fitzgerald maintained a Hold rating on Bristol-Myers Squibb, with a price target of $45.00. Th...

Cantor Fitzgerald Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is conducting a Pha...

Bristol-Myers Squibb’s Promising SLE Treatment: A Study Update

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. In a significant move for cancer treatment, Bristol-Myer...

Bristol-Myers Squibb’s New Study on Izalontamab Brengitecan: A Potential Game-Changer in Lung Cancer Treatment

Bristol-Myers Squibb Company (($BMY)), Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer and Bristol-Myers Squibb are...

Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment

Bristol-Myers Squibb’s Innovative Drug Formulation Study: Market Insights

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb Company is conducti...

Bristol-Myers Squibb’s New Study on BMS-986504: A Potential Game-Changer in Cancer Treatment

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb, in collaboration w...

Bristol-Myers Squibb’s Innovative Approach to Multiple Myeloma: A Study Update

Bristol-Myers Squibb’s Innovative AML and MDS Study: A Potential Game-Changer?

Bristol-Myers Squibb’s New Study on Alzheimer’s Psychosis Treatment: A Potential Market Game-Changer

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is conducting a stu...

Bristol-Myers Squibb’s New Study on Idecabtagene Vicleucel: What Investors Should Know

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is conducting a Fre...

Bristol-Myers Squibb’s New Study on Nivolumab: Market Implications and Progress

In a report released today, from Berenberg Bank reiterated a Buy rating on Bloomsbury Publishing, with a price target of p825.00. The company’s sha...

Market Cap	$95.80B	P/E Ratio	7.10
52W High	$63.33	52W Low	$42.52
Div Yield	248.0%	Payout Ratio	1939.6%
EPS Growth 3Y	-50.4%	52W Position	18.8%
Overall Score	62	Value Score	75
Quality Score	--	Technical Score	50

EPS Current Est	$6.54	EPS Next Est	$6.01
EPS Growth Est	-8.1%	DPS Growth 3Y	6.4%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$46.43	+1.07%	8.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$46.43	+1.1%	8.43M
3
4
5
6

BMY

BMY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel